Curcumin Sensitizes Lung Cancer Cells to Cisplatin-Induced Apoptosis Through Superoxide Anion-Mediated Bcl-2 Degradation

REFERENCES

• Nishio K., Nakamura T., Koh Y., Suzuki T., Fukumoto H., Saijo N. Drug resistance in lung cancer. Curr Opin Oncol 1999; 11: 109–115
   PubMedGoogle Scholar
• Wong E., Giandomenico C. M. Current status of platinum-based antitumor drugs. Chem Rev 1999; 99: 2451–2466
   PubMed Web of Science ®Google Scholar
• Seve P., Dumontet C. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anti-Canc Agents 2005; 5: 73–88
   PubMedGoogle Scholar
• Roth B. J., Bajorin D. F. Advanced bladder cancer: the need to identify new agents in the post-M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) world. J Urol 1995; 153: 894–900
   PubMed Web of Science ®Google Scholar
• Hoffman P. C., Mauer A. M., Vokes E. E. Lung cancer. Lancet 2000; 355: 479–485
   PubMed Web of Science ®Google Scholar
• Kelly S. L., Basu A., Teicher B. A., Hacker M. P., Hamer D. H., Lazo J. S. Overexpression of metallothionein confers resistance to anticancer drugs. Science 1988; 241: 1813–1815
   PubMed Web of Science ®Google Scholar
• Godwin A. K., Meister A., O'Dwyer P. J., Huang C. S., Hamilton T. C., Anderson M. E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA 1992; 1: 3070–3074
   Google Scholar
• Andrews P. A., Schiefer M. A., Murphy M. P., Howell S. B. Enhanced potentiation of cisplatin cytotoxicity in human ovarian carcinoma cells by prolonged glutathione depletion. Chem Biol Interact 1988; 65: 51–58
   PubMed Web of Science ®Google Scholar
• Miyake H., Hanada N., Nakamura H., Kagawa S., Fugiwara T., Hara I., Eto H., Gohji K., Arakawa S., Kamidono S., Saya H. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer. Oncogene 1998; 19: 933–943
   Google Scholar
• Li D., Ueta E., Kimura T., Yamamoto T., Osaki T. Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 2004; 95: 644–650
   PubMed Web of Science ®Google Scholar
• Raspollini M. R., Castiglione F., Degl'Innocenti D. R., Baroni G., Amunni G., Villanucci A., Taddei G. L. Bcl-2 in ovarian carcinoma: a clinicopathologic, immunohistochemical, and molecular study. Pathologica 2004; 96: 465–469
   PubMedGoogle Scholar
• Yang X., Zheng F., Xing H., Gao Q., Wei W., Lu Y., Wang S., Zhou J., Hu W., Ma D. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. Cancer Res Clin Oncol 2004; 130: 423–428
   PubMed Web of Science ®Google Scholar
• Kausch I., Jiang H., Thode B., Doehn C., Kruger S., Joeham D. Inhibition of bcl-2 enhances the efficacy of chemotherapy in renal cell carcinoma. Eur Urol 2005; 47: 703–709
   PubMed Web of Science ®Google Scholar
• Chanvorachote P., Nimmannit U., Stehlik C., Wang L., Jiang B., Ongpipatanakul B., Rojanasakul Y. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res 2006; 66: 6353–6360
   PubMed Web of Science ®Google Scholar
• Ikegaki N., Katsumata M., Minna J. Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res 1994; 54: 6–8
   PubMed Web of Science ®Google Scholar
• Ben-Ezra J. M., Kornstein M. J., Grimes M. M. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994; 145: 1036–1040
   PubMed Web of Science ®Google Scholar
• Hochstrasser M. Ubiquitin-dependent protein degradation. Annu Rev Genet 1996; 30: 405–439
   PubMed Web of Science ®Google Scholar
• Ciehanover A., Schwartz A. L. The ubiquitin-proteasome pathway: the complexity and myriad functions of protein deaths. Proc Natl Acad Sci USA 1998; 95: 2727–2730
   PubMed Web of Science ®Google Scholar
• Conney A. H., Lysz T., Ferraro T., Abidi T. F., Manchand P. S., Laskin J. D., Huang M. T. Inhibitory effect of curcumin and some related dietary compounds on tumor promotion and arachidonic acid metabolism in mouse skin. Adv Enzyme Regul 1991; 31: 385–396
   PubMedGoogle Scholar
• Huang M. T., Lysz T., Ferraro T., Abidi T. F., Laskin J. D., Conney A. H. Inhibitory effects of curcumin on in vitrolipoxygenase and cyclooxygenase activities in mouse epidermis. Cancer Res 1991; 51: 813–819
   PubMed Web of Science ®Google Scholar
• Ruby A. J., Kuttan G., Babu K. D., Rajasekharan K. N., Kuttan R. Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett 1995; 20: 79–83
   Google Scholar
• Huang M. T., Newmark H. L., Frenkel K. Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem Suppl 1997; 27: 26–34
   PubMedGoogle Scholar
• Ireson C. R., Jones D. J., Orr S., Coughtrie M. W., Boocock D. J., Williams M. L., Farmer P. B., Steward W. P., Gescher A. J. Metabolism of the cancer chemopreventive agent curcumin in human and rat intestine. Cancer Epidemiol Biomarkers Prev 2002; 11: 105–111
   PubMed Web of Science ®Google Scholar
• Aggarwal B. B., Kumar A., Bharti A. C. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003; 23: 363–398
   PubMed Web of Science ®Google Scholar
• Yoshino M., Haneda M., Naruse M., Htay H. H., Tsubouchi R., Qiao S. L., Li W. H., Murakami K., Yokochi T. Prooxidant activity of curcumin: copper-dependent formation of 8-hydroxy-2′-deoxyguanosine in DNA and induction of apoptotic cell death. Toxicol In Vitro 2004; 18: 783–789
   PubMed Web of Science ®Google Scholar
• Atsumi T., Fujisawa S., Tonosaki K. Relationship between intracellular ROS production and membrane mobility in curcumin- and tetrahydrocurcumin-treated human gingival fibroblasts and human submandibular gland carcinoma cells. Oral Dis 2005; 11: 236–242
   PubMed Web of Science ®Google Scholar
• Notarbartolo M., Poma P., Perri D., Dusonchet L., Cervello M., D'Alessandro N. Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-κ B activation levels and in IAP gene expression. Cancer Lett 2005; 224: 53–65
   Google Scholar
• Schweyer S., Soruri A., Heintze A., Radzun H. J., Fayyazi A. The role of reactive oxygen species in cisplatin-induced apoptosis in human malignant testicular germ cell lines. Int J Oncol 2004; 25: 1671–1676
   PubMed Web of Science ®Google Scholar
• Wu Y. J., Muldoon L. L., Neuwelt E. A. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 2005; 312: 424–431
   PubMed Web of Science ®Google Scholar
• Park M. S., Leon M. D., Devarajan P. Cisplatin induces apoptosis in LLC-PK1 cells via activation of mitochondrial pathways. J Am Soc Nephrol 2002; 13: 858–865
   PubMed Web of Science ®Google Scholar
• Henkels K. M., Turchi J. J. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and-independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines. Cancer Res 1999; 59: 3077–3083
   PubMed Web of Science ®Google Scholar
• Melendez-Zaigla J., Cruz E., Maldonado V., Espinoza A. M. Mitochondrial changes during the apoptotic process of HeLa cells exposed to cisplatin. Biochem Mol Biol Int 1999; 47: 765–771
   PubMedGoogle Scholar
• Green D. R., Reed J. C. Mitochondria and apoptosis. Science 1998; 28: 1309–1312
   Google Scholar
• Breitschopf K., Haendeler J., Malchow P., Zeiher A. M., Dimmeler S. Posttranslational modification of bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway. Mol Cell Biol 2000; 20: 1886–1896
   PubMed Web of Science ®Google Scholar
• Sharma H., Sen S., Singh N. Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther 2005; 4: 949–955
   PubMed Web of Science ®Google Scholar
• Muroi M., Takasu A., Yamasaki M., Takatsuki A. Folimycin (concanamycin A), an inhibitor of V-type H (+)-ATPase, blocks cell-surface expression of virus-envelope glycoproteins. Biochem Biophys Res Commun 1993; 193: 999–1005
   PubMed Web of Science ®Google Scholar
• Jung E. M., Lim J. H., Lee T. J., Park J. W., Choi K. S., Kwon T. K. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis 2005; 26: 1905–1913
   PubMed Web of Science ®Google Scholar
• Deeb D., Jiang H., Gao X., Hafner M. S., Wong H., Divine G., Chapman R. A., Dulchavsky S. A., Gautam S. C. Curcumin sensitizes prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L by inhibiting nuclear factor-kappaB through suppression of IkappBalpha phosphorylation. Mol Cancer Ther 2005; 3: 803–812
   Web of Science ®Google Scholar
• Weir N. M., Selvendiran K., Kutala V. K., Tong L., Vishwanath S., Rajaram M., Vishwanath S., Rajaram M., Tridandapani S., Anant S., Kuppusamy P. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by modulating Akt and p38 MAPK. Cancer Biol Ther 2007; 6: 178–184
   PubMed Web of Science ®Google Scholar
• Singh S., Aggarwal B. B. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane). J Biol Chem 1995; 270: 24995–25000
   PubMed Web of Science ®Google Scholar
• Aggarwal S., Ichikawa H., Takada Y., Sandur S. K., Shishodia S., Aggrawal B. B. Curcumin (diferuloylmethane) down-regulates expression of cell proliferation, antiapoptotic, and metastatic gene products through suppression of Iκ Bα kinase and AKT activation. Mol Pharmacol 2006; 69: 195–206
   PubMed Web of Science ®Google Scholar
• Woo J. H., Kim Y. H., Choi Y. J., Kim D. G., Lee K. S., Bae J. H., Min D. S., Chang J. S., Jeong Y. J., Lee Y. H., Park J. W., Kwon T. K. Molecular mechanisms of curcumin-induced cytotoxicity: induction of apoptosis through generation of reactive oxygen species, down-regulation of Bcl-XL and IAP, the release of cytochrome c and inhibition of Akt. Carcinogenesis 2003; 24: 1199–1208
   PubMed Web of Science ®Google Scholar
• Siddick Z. H. Cisplatin: mode of action and molecular basis of resistance. Oncogene 2003; 22: 7265–7279
   PubMed Web of Science ®Google Scholar
• Adams J. M., Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci 2001; 26: 61–66
   PubMed Web of Science ®Google Scholar
• Ohsaki Y., Toyoshima E., Fujiuchi S., Matsui H., Hirata S., Miyokawa N., Kubo Y., Kikuchi K. Bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time. Clin Cancer Res 1996; 2: 915–920
   PubMed Web of Science ®Google Scholar
• Ohmori T., Podack E. R., Nishio K., Takahashi M., Miyahara Y., Takeda Y., Kubota N., Funayama Y., Ogasawara H., Ohira T., Ohta S., Saijo N. Apoptosis of lung cancer cells caused by some anti-cancer agents (MMC, CPT-11, ADM) is inhibited by bcl-2. Biochem Biophys Res Commun 1993; 192: 30–36
   PubMed Web of Science ®Google Scholar
• Numsen H. Mitochondrial reactive oxygen species affect sensitivity to curcumin-induced apoptosis. Free Radic Biol Med 2008; 44: 1382–1393
   PubMed Web of Science ®Google Scholar
• Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochem Biophys Acta 1998; 1366: 53–67
   PubMed Web of Science ®Google Scholar
• Kruidering M., Water B. V.D., Heer E. D., Mulder G. J., Nagelkerke J. F. Cisplatin-induced nephrotoxicity in porcine proximal tubular cells: mitochondrial dysfunction by inhibition of complexes I to IV of the respiratory chain. J Pharmacol Exp Ther 1997; 280: 638–649
   PubMed Web of Science ®Google Scholar
• Bhaumik S., Anjum R., Rangaraj N., Pardhasaradhi B. V.V., Khar A. Curcumin-mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. FEBS Lett 1999; 456: 311–314
   PubMed Web of Science ®Google Scholar